Abstract:1 The effect of pirenzepine, a muscarinic antagonist considered to be selective for M1 receptors, was studied on bronchoconstriction and bradycardia elicited by preganglionic stimulation of the parasympathetic vagal nerves and by i.v. injections of acetylcholine (ACh) in anaesthetized guinea- 4 Propranolol (1 mg kg-) increased control bronchoconstrictor responses elicited by ACh and vagal stimulation but did not alter the potency of pirenzepine for postjunctional receptors in heart or lung. However, pirenzepin… Show more
“…Thus, it is unlikely that sympathetic reflex responses to the lung were elicited by either stimulus. This contrasts with results obtained in the anaesthetized guinea-pig, where bronchoconstrictor stimuli are increased by propranolol due to blockade of a sympathetic bronchodilator reflex (McCulloch et al, 1967;Maclagan et al, 1989). The lack of a sympathetic bronchodilator reflex in the rabbit may be due to the effects of the general anaesthetic or to the absence of a sympathetic innervation of airway smooth muscle in that species (Mann, 1971).…”
Section: Discussioncontrasting
confidence: 53%
“…Figure 3 and the 5 I bronchoconstriction due to blockade of neuronal receptors (Fryer & Maclagan, 1984;Maclagan et al, 1989).…”
Section: Resultsmentioning
confidence: 99%
“…In the lung in the guinea-pig, the sympathetic nerves innervating airway smooth muscle contain Ml receptors that facilitate transmission (Maclagan et al, 1989) but this mechanism has not yet been demonstrated in the lung in any other species. On the other hand, the parasympathetic nerves innervating the lung have been demonstrated to contain M2 receptors in several species.…”
Section: Discussionmentioning
confidence: 99%
“…Bronchoconstriction was recorded (as described by Maclagan et al, 1989) as an increase in pulmonary inflation pressure (Ppi) over the basal insufflation pressure change produced by the pump. The experiments were repeated in a second group of animals which received propranolol (1 mg kg 1, i.v.)…”
1 The effect of muscarinic antagonists considered to be selective for M1 receptors (pirenzepine) and for M2 receptors (gallamine) were studied on bronchoconstriction and bradycardia elicited by stimulation of the vagal nerves and by i.v. acetylcholine (ACh) in anaesthetized rabbits. 2 Pirenzepine was equipotent as an antagonist of ACh-induced responses at postjunctional muscarinic receptors in the heart, lung and blood vessels, whereas gallamine was at least ten times less potent at pulmonary and vascular muscarinic receptors. Thus, gallamine never caused complete inhibition of bronchoconstrictor or hypotensive responses to i.v. ACh, whereas doses of pirenzepine in excess of 1 pmol kg1-abolished all muscarinic responses. 3 In the lung, both antagonists inhibited bronchoconstriction caused by vagal stimulation and ACh-induced bronchoconstriction to the same extent (pirenzepine, mean ED50 65 + 22 and 130 + 28nmolkg-1 respectively; gallamine, ED50> 10,OOOnmolkg-1 for both responses).Enhancement of vagally-induced bronchoconstriction was never observed. 4 In the heart, however, both pirenzepine and gallamine were ten times less potent as antagonists of vagally-induced bradycardia than of ACh-induced bradycardia. This differential blockade was unaltered by propranolol (1 mg kg-1) pretreatment. 5 It is concluded that there is no evidence for M1 or M2 muscarinic receptors in the pulmonary innervation of the rabbit and the potency of the antagonists in abolishing vagally-induced bronchoconstriction was consistent with blockade of M3 muscarinic receptors on airway smooth muscle. 6 The results suggest that M2 muscarinic receptors may exert an inhibitory effect on transmission in the parasympathetic nerves innervating the heart in the rabbit. Blockade of such neuronal receptors would increase transmitter output to the atrial cells and explain the low potency of both antagonists in abolishing vagally-induced bradycardia in the rabbit.
“…Thus, it is unlikely that sympathetic reflex responses to the lung were elicited by either stimulus. This contrasts with results obtained in the anaesthetized guinea-pig, where bronchoconstrictor stimuli are increased by propranolol due to blockade of a sympathetic bronchodilator reflex (McCulloch et al, 1967;Maclagan et al, 1989). The lack of a sympathetic bronchodilator reflex in the rabbit may be due to the effects of the general anaesthetic or to the absence of a sympathetic innervation of airway smooth muscle in that species (Mann, 1971).…”
Section: Discussioncontrasting
confidence: 53%
“…Figure 3 and the 5 I bronchoconstriction due to blockade of neuronal receptors (Fryer & Maclagan, 1984;Maclagan et al, 1989).…”
Section: Resultsmentioning
confidence: 99%
“…In the lung in the guinea-pig, the sympathetic nerves innervating airway smooth muscle contain Ml receptors that facilitate transmission (Maclagan et al, 1989) but this mechanism has not yet been demonstrated in the lung in any other species. On the other hand, the parasympathetic nerves innervating the lung have been demonstrated to contain M2 receptors in several species.…”
Section: Discussionmentioning
confidence: 99%
“…Bronchoconstriction was recorded (as described by Maclagan et al, 1989) as an increase in pulmonary inflation pressure (Ppi) over the basal insufflation pressure change produced by the pump. The experiments were repeated in a second group of animals which received propranolol (1 mg kg 1, i.v.)…”
1 The effect of muscarinic antagonists considered to be selective for M1 receptors (pirenzepine) and for M2 receptors (gallamine) were studied on bronchoconstriction and bradycardia elicited by stimulation of the vagal nerves and by i.v. acetylcholine (ACh) in anaesthetized rabbits. 2 Pirenzepine was equipotent as an antagonist of ACh-induced responses at postjunctional muscarinic receptors in the heart, lung and blood vessels, whereas gallamine was at least ten times less potent at pulmonary and vascular muscarinic receptors. Thus, gallamine never caused complete inhibition of bronchoconstrictor or hypotensive responses to i.v. ACh, whereas doses of pirenzepine in excess of 1 pmol kg1-abolished all muscarinic responses. 3 In the lung, both antagonists inhibited bronchoconstriction caused by vagal stimulation and ACh-induced bronchoconstriction to the same extent (pirenzepine, mean ED50 65 + 22 and 130 + 28nmolkg-1 respectively; gallamine, ED50> 10,OOOnmolkg-1 for both responses).Enhancement of vagally-induced bronchoconstriction was never observed. 4 In the heart, however, both pirenzepine and gallamine were ten times less potent as antagonists of vagally-induced bradycardia than of ACh-induced bradycardia. This differential blockade was unaltered by propranolol (1 mg kg-1) pretreatment. 5 It is concluded that there is no evidence for M1 or M2 muscarinic receptors in the pulmonary innervation of the rabbit and the potency of the antagonists in abolishing vagally-induced bronchoconstriction was consistent with blockade of M3 muscarinic receptors on airway smooth muscle. 6 The results suggest that M2 muscarinic receptors may exert an inhibitory effect on transmission in the parasympathetic nerves innervating the heart in the rabbit. Blockade of such neuronal receptors would increase transmitter output to the atrial cells and explain the low potency of both antagonists in abolishing vagally-induced bradycardia in the rabbit.
“…An M1 receptordependent pathway counteracts cholinergic bronchoconstriction, possibly via the release of a relaxing agent (8); both respiratory epithelia and sympathetic nerve terminals within bronchial smooth muscle are equipped with M1 receptors (7,26) and releasable bronchodilating agents, such as nitric oxide and prostaglandin E 2 (27). Studies with the M1 receptor-preferring antagonist, pirenzepine, have also suggested the existence of pulmonary M1 receptors modulating airway diameter (28).…”
Rationale:The human cholinergic receptor muscarinic-1 (CHRM1) is widely distributed in the lungs. In patients with asthma, CHRM1 may be involved in airway constriction, airway epithelial cell proliferation, and airway inflammation. The CHRM1 gene is located on chromosome 11q13, which is one of the candidate loci for asthma and atopy. Objectives: To determine the role of the CHRM1 gene polymorphisms in asthma. Methods: We studied nine single-nucleotide polymorphismsϾ G, and ؉5455G Ͼ T) in a case-control study using 326 patients with asthma and 333 healthy control subjects. We also examined functional consequences of the ؊9697C Ͼ T and ؊4953A Ͼ G polymorphisms at the regulatory region using an mRNA reporter assay. Measurements and Main Results: Two common single-nucleotide polymorphisms (؊9697C Ͼ T and ؊4953A Ͼ G) were associated with asthma. The odds ratio for the TT homozygotes at the ؊9697C Ͼ T polymorphism was 0.29 compared with the CC homozygotes (95% confidence interval, 0.12-0.73; p ϭ 0.008), and the odds ratio for the GG homozygotes at the ؊4953A Ͼ G polymorphism was 1.86 compared with the AA homozygotes (95% confidence interval, 1.04-3.34; p ϭ 0.038). Haplotype analysis showed that the ؊9697T/ ؊6965T/؊4953A haplotype was associated with a lower risk of asthma (p ϭ 0.00055) and the ؊9697C/؊6965T/؊4953G haplotype was associated with an increased risk of asthma (p ϭ 0.020). The ؊9697T/؊4953A haplotype was also associated with lower luciferase activity in vitro compared with the ؊9697C/؊4953G haplotype. Conclusions: This study, together with an in vitro functional study, suggests that the CHRM1 gene is an important susceptibility locus for asthma on chromosome11q13.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.